Regeneron hit with FDA rejection for blood cancer therapy
The agency said it required the confirmatory portion of odronextamab’s Phase III trial.
The agency said it required the confirmatory portion of odronextamab’s Phase III trial.
The AI-QCT ISCHEMIA software uses AI to analyse atherosclerosis and blood vessel shapes from CCTA images.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
Gedeon Richter adopts TransPerfect’s trial management solutions
Artificial intelligence identified two evolutionary pathways of prostate cancer
BeiGene spin-out Pi Health raises $30m to uptick cancer trial enrolment
Psychedelic treatments for mental health: Is there substance behind the hype?